OnKure and Reneo Pharmaceuticals complete merger [Yahoo! Finance]
OnKure Therapeutics, Inc. - Class A (OKUR)
Company Research
Source: Yahoo! Finance
The shares will commence trading on the Nasdaq Global Market under the "OKUR" ticker symbol. The companies first reached an agreement to combine in an all-stock deal in May 2024. OnKure has also finalised a $65m private placement backed by both new and existing investors. This strategic financial move will extend the company's cash runway through multiple clinical readouts until the fourth quarter of 2026. The leadership of the merged company will include Nicholas Saccomano as president and CEO, Samuel Agresta as chief medical officer, Dylan Hartley as chief scientific officer and Jason Leverone as chief financial officer. The board of directors will feature a mix of members from both OnKure and Reneo, along with Valerie Jansen, who joined at the merger's closure. Saccomano stated: “We are ecstatic to finalise this merger, and move to accelerate the development of our mutant-specific PI3Ka inhibitor portfolio. “Combined with our unique expertise in PI3K-mutated cancers,
Show less
Read more
Impact Snapshot
Event Time:
OKUR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OKUR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OKUR alerts
High impacting OnKure Therapeutics, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
OKUR
News
- OnKure Therapeutics (NASDAQ: OKUR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.MarketBeat
- OnKure to Present at the Stifel 2024 Healthcare ConferenceGlobeNewswire
- OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium [Yahoo! Finance]Yahoo! Finance
- OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer SymposiumGlobeNewswire
- OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond [Seeking Alpha]Seeking Alpha
OKUR
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/7/24 - Form 424B3
- OKUR's page on the SEC website